BioCentury | Nov 24, 2014
Company News

BSD Medical management update

BSD Medical Corp. (NASDAQ:BSDM), Salt Lake City, Utah Business: Cancer Hired: Clint Carnell as president, CEO, and a director, formerly an executive in residence at Covidien plc ; he succeeds Harold Wolcott WIR Staff...
BioCentury | Sep 1, 2014
Financial News

BSD Medical financial update

BSD Medical Corp. (NASDAQ:BSDM), Salt Lake City, Utah Business: Cancer Date announced: 2014-08-13 Note: BSD received notice from NASDAQ indicating that the company is not in compliance with the $1 minimum bid price requirement for...
BioCentury | Apr 15, 2013
Financial News

BSD Medical completes direct public offering

BSD Medical Corp. (NASDAQ:BSDM), Salt Lake City, Utah Business: Cancer Date completed: 4/9/13 Type: Direct public offering Raised: $5 million Shares: 4.1 million Price: $1.23 Shares after offering: 27 million Placement agent: Roth Capital Partners...
BioCentury | Dec 24, 2012
Clinical News

BSD-2000 Hyperthermia System: Phase I/II started

...chemotherapy. The device has CE Mark approval in Europe and is also approved in China. BSD Medical Corp....
BioCentury | Feb 28, 2011
Clinical News

BSD-2000 Hyperthermia System regulatory update

...frequency). The system has CE Mark approval in Europe and is also approved in China. BSD Medical Corp....
BioCentury | Nov 22, 2010
Financial News

BSD Medical completes direct public offering

BSD Medical Corp. (NASDAQ:BSDM), Salt Lake City, Utah Business: Cancer Date completed: 11/15/10 Type: Direct public offering Raised: $10.4 million Shares: 1.8 million Price: $5.97 Shares after offering: 28.8 million Placement agent: Roth Capital Partners...
BioCentury | May 10, 2010
Clinical News

BSD-2000 Hyperthermia System: Phase III data

...CE Mark approval in Europe and is also approved in China, is under FDA review. BSD Medical Corp....
BioCentury | May 10, 2010
Financial News

BSD Medical completes direct public offering

BSD Medical Corp. (NASDAQ: BSDM), Salt Lake City, Utah Business: Cancer Date completed: 5/3/10 Type: Direct public offering Raised: $2.5 million Shares: 1.6 million Price: $1.52 Shares after offering: 24.9 million Placement agent: Roth Capital...
BioCentury | Feb 15, 2010
Clinical News

BSD-2000: Phase III started

...with or without the BSD-2000 Hyperthermia System in pancreatic cancer patients with surgical tumor resection. BSD Medical Corp....
BioCentury | Apr 25, 2000
Clinical News

BSD Medical to start Phase I/II study

BSDM said it will start a U.S. Phase I/II trial combining hyperthermia with liposome-encapsulated doxorubicin to treat ovarian cancer. BC Staff...
Items per page:
1 - 10 of 10
BioCentury | Nov 24, 2014
Company News

BSD Medical management update

BSD Medical Corp. (NASDAQ:BSDM), Salt Lake City, Utah Business: Cancer Hired: Clint Carnell as president, CEO, and a director, formerly an executive in residence at Covidien plc ; he succeeds Harold Wolcott WIR Staff...
BioCentury | Sep 1, 2014
Financial News

BSD Medical financial update

BSD Medical Corp. (NASDAQ:BSDM), Salt Lake City, Utah Business: Cancer Date announced: 2014-08-13 Note: BSD received notice from NASDAQ indicating that the company is not in compliance with the $1 minimum bid price requirement for...
BioCentury | Apr 15, 2013
Financial News

BSD Medical completes direct public offering

BSD Medical Corp. (NASDAQ:BSDM), Salt Lake City, Utah Business: Cancer Date completed: 4/9/13 Type: Direct public offering Raised: $5 million Shares: 4.1 million Price: $1.23 Shares after offering: 27 million Placement agent: Roth Capital Partners...
BioCentury | Dec 24, 2012
Clinical News

BSD-2000 Hyperthermia System: Phase I/II started

...chemotherapy. The device has CE Mark approval in Europe and is also approved in China. BSD Medical Corp....
BioCentury | Feb 28, 2011
Clinical News

BSD-2000 Hyperthermia System regulatory update

...frequency). The system has CE Mark approval in Europe and is also approved in China. BSD Medical Corp....
BioCentury | Nov 22, 2010
Financial News

BSD Medical completes direct public offering

BSD Medical Corp. (NASDAQ:BSDM), Salt Lake City, Utah Business: Cancer Date completed: 11/15/10 Type: Direct public offering Raised: $10.4 million Shares: 1.8 million Price: $5.97 Shares after offering: 28.8 million Placement agent: Roth Capital Partners...
BioCentury | May 10, 2010
Clinical News

BSD-2000 Hyperthermia System: Phase III data

...CE Mark approval in Europe and is also approved in China, is under FDA review. BSD Medical Corp....
BioCentury | May 10, 2010
Financial News

BSD Medical completes direct public offering

BSD Medical Corp. (NASDAQ: BSDM), Salt Lake City, Utah Business: Cancer Date completed: 5/3/10 Type: Direct public offering Raised: $2.5 million Shares: 1.6 million Price: $1.52 Shares after offering: 24.9 million Placement agent: Roth Capital...
BioCentury | Feb 15, 2010
Clinical News

BSD-2000: Phase III started

...with or without the BSD-2000 Hyperthermia System in pancreatic cancer patients with surgical tumor resection. BSD Medical Corp....
BioCentury | Apr 25, 2000
Clinical News

BSD Medical to start Phase I/II study

BSDM said it will start a U.S. Phase I/II trial combining hyperthermia with liposome-encapsulated doxorubicin to treat ovarian cancer. BC Staff...
Items per page:
1 - 10 of 10